Novartis expands global collaboration with Amgen to commercialize first-in-class AMG 334
Novartis announced an expanded commercialization agreement with Amgen for AMG 334 (erenumab), which is being investigated for prevention of migraine. The companies will co-commercialize AMG 334 in the US. Novartis will retain exclusive rights to commercialize the drug in rest of world and Canada. April 24, 2017